distractions.â
Crawford nodded. âIâve always been in favor of too much testing over not enough.â
Kelly stood. âGood. Glad you see it that way.â
Crawford and Pembroke rose.
âWho is it you want me to talk with?â Crawford asked.
âDalton,â Kelly replied. âThanks, Gavin.â He extended his hand and gave a nod to Pembroke. âThanks to both of you.â He turned away and caught the eye of another senator.
Crawford looked at Pembroke. âIâm . . . eh . . . does Tom think I have an in with Roanne?â
âNo. Actually, he sees it the other way. She looks to you as an ally. You know, she seems to have rubbed some folks the wrong way.â
âI wasnât aware of that. Sheâs new, but I thought she had lots of friends.â
âMostly H.T.âs friends, who accommodate her.â
âOh,â was all Crawford decided to say. He didnât particularly agree with Pembrokeâs assessment, but it wasnât worth challenging. âSo . . . eh . . . what exactly is her position?â
âSheâs not following the party line. Itâs very straightforward. FDA says there are serious side effects. After those major recalls awhile back, Tom doesnât want a distraction caused by an unproven drug. We have too much going with the pharmas already.â
This seemed out-of-step with the way Tom operated, Crawford thought. For some reason, he didnât want the whip handling it. He felt uncomfortable about this . . . it put him in a bit of a bind. He liked Dalton, but he also liked the progress he had been making in the caucus. Maybe this was a leadership test. Free discussion had never been a problem amongst the colleagues. However, Kelly wanted unanimity and had chosen him to get it.
Pembroke interrupted his thoughts. âThereâs stuff whipping around in Appropriations and in Finance, aside from all the issues with Medicare and the cost of prescription drugs.â
âYeah, itâs piling up. Okay. Has anyone lobbied Roanne about this, prior to me?â
âWe donât know what ties she has, or H.T. had, with the pharmaceutical company applying for approval, if any.â
Another non-answer. âWhatâs the name of this drug and the company?â
âItâs called Tutoxtamen and the pharma is Rogers, up in New Jersey.â
7
T he large hotel ballroom was set up auditorium-style, with a raised dais at one end, on which sat a podium and four straight-back chairs.
A banner behind the dais announced: Rogers Pharmaceuticals, Inc.âs Annual Stockholders Meeting.
Harley S. Rogers, eighty-three-year-old founder, chairman, and CEO of Rogers Pharmaceuticals, Inc., was ramrod in stature and leadership with a strong timbre to his voice. He normally stayed behind the scenes, leaving his son Sherman, president and COO of Rogers, to be the public face. Harley was absorbed with the product side.
And today the product was his miracle drug, Tutoxtamen. That damned FDA fabricated findings saying there were side effects , Harley rued, standing in the wings waiting to go on. All the test results had been astoundingly positive. Expectations verged on the stupendous. Stockholders, the public, and the media were ecstatic.
The FDA had leaked there were side-effect problems, and his companyâs stock had fallen precipitously, over forty percent and now teeteringâ dipping and rising on every whisper of news. Harley estimated heâd lost fifty percent of his net worth.
A scientist first, Harley Rogers had always hoped heâd discover a miracle drug that would rid the world of one of its horrible diseases. He had that now in Tutoxtamen.
Nevertheless, it seemed as though the pharmas had convinced the FDA there was a problem. That was why he was coming forward today. The old soldier needed to take the stage and tell everyone his drug worked. Heâd illustrate his remarks with hundreds of
David Levithan, Rachel Cohn